ClinicalTrials.gg
RecruitingNCT075312514TAZPowerUpdated Nov 9, 2026

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

A Phase 4 interventional study of Elamipretide and Placebo in Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Recruiting at 4 sites in 4 countries. Open to male participants aged 5 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Stealth BioTherapeutics Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 9, 2026First site in AustraliaStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
5 Years to 55 Years
Sex
Male
01

Study summary

Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily SC injection of elamipretide in subjects with genetically confirmed BTHS for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States(FORZINITY™) under the accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.

Read the detailed description

The SPIBA-401 trial is a post marketing Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily subcutaneous (SC) injection of elamipretide in subjects with genetically confirmed Barth syndrome (BTHS) for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States under the name FORZINITY™ as a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved in the United States under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.

02

Conditions studied

  • Barth Syndrome

Keywords

  • BTHS
  • Ultra Rare X-Linked Mitochondrial Disorder
  • Genetic Defect in TAZ Gene
03

In context

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Willing and able to provide signed form (ICF) prior to participation in any trial-related procedures. If applicable, informed consent in writing from parent(s) or legally-acceptable representative(s) and, informed assent from subject (if age appropriate according to local requirements) should be provided.
  2. Agrees to adhere to the trial requirements for the length of the trial.
  3. Must have genetically confirmed Barth Syndrome (pathogenic variant in the TAZ gene)
  4. Male aged ≥ 5 years at time of the Screening Visit
  5. of ≥ 50% by 3-D Echocardiogram at the Screening Visit.
  6. For subjects with a medical history of cardiomyopathy, must be on a stable regimen (unchanged and constant) of background heart failure medications for at least 3 months prior to the Screening Visit.
  7. Able to administer Medicinal Product (IMP) or have an appropriate designee who can administer the IMP (i.e., a capable family member or a caregiver).
  8. Subjects with female partners of must be willing to use a highly effective method of (e.g., abstinence, dual method of contraception) from the date they sign the ICF until 28 days after the last dose of IMP.

Key Exclusion Criteria:

  1. Unable to perform the required functional tests or undergo echocardiography.
  2. History of solid organ transplant, except successful cardiac transplantation > 12 months prior to screening, if, in the opinion of the Investigator, there is no evidence of organ rejection and post-transplant pharmacotherapy, is stable, and does not pose additional safety risk to participant.
  3. Patients with an implantable cardioverter defibrillator (ICD) and with a known occurrence of ICD discharge in the 3 months prior to the Screening Visit.
  4. Current placement on the waiting list for heart transplantation.
  5. Hospitalization for heart failure within 6 months prior to the Screening Visit.
  6. Any disease or medical condition that in the opinion of the Investigator would prevent the subject from successfully participating in the trial and reliably completing the assessments or might confound trial results.
  7. Has a history of a systemic eosinophilic illness
  8. Estimated (eGFR) of \< 30 mL/min at the Screening Visit (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula for subjects >16 years of age and the Schwartz 2009 formula for subjects 5-16 years of age).
  9. Active or any other cancer from which the subject has been cancer-free for \< 2 years. Localized squamous or non-invasive basal cell skin carcinomas are allowed, if appropriately treated prior to Screening.
  10. Participation in other investigational drug or device clinical trials within 30 days or 5 half-lives (whichever is longer) of Screening; or is currently enrolled in a non-interventional clinical trial that, in the opinion of the Investigator, may be potentially confounding to the results of the current trial.
  11. History of allergic reaction to the IMP or any of its components.
  12. Prior participation in any elamipretide trial or expanded access programs.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Elamipretide

    Elamipretide - aqueous, sterile 5.0 mL single-patient, ready to use, multi-dose glass vial containing 3.5 mL of elamipretide solution (elamipretide \[80 mg/mL\],

    Drug: Elamipretide

  • Placebo comparator
    Placebo

    Matching Placebo-aqueous, sterile 5.0 mL single-patient, ready to use, multi-dose glass vial containing will be composed of 3.5mL of sodium chloride, phosphate buffer, and benzyl alcohol similar to excipients in active drug but without the active drug substance

    Drug: Placebo

Interventions

  • sub cutaneous injection

    Also known as: elamipretide hydrochloride

  • DrugPlacebo

    sub cutaneous injection

06

What researchers measure

Primary outcomes

  1. Primary Efficacy End Point

    -change in the composite normalized score of the three functional tests: Six-minute walk test (6MWT), the triple-timed up and go test (3TUG), and the Five times sit-to-stand test (5XSST) from baseline to 72 weeks of treatment

    Time frame: 72 weeks

Secondary outcomes

  1. Secondary Efficacy End Point 1

    \- Change in 6Minute Walk Test from Baseline to Week 72

    Time frame: 72 weeks

  2. Secondary Efficacy End Point 2

    -Change in 3Timed Up and Go Test from Baseline to Week 72

    Time frame: 72 weeks

  3. Secondary Efficacy End Point 3

    -Change in 5XSit to Stand Test from Baseline to Week 72

    Time frame: 72 weeks

  4. Secondary Efficacy End Point 4

    -Change in Patient Global Impression of Severity Scale (PGI-S) score from Baseline to Week 72

    Time frame: 72 weeks

  5. Secondary Efficacy End Point 5

    Change in Clinician Global Impression of Severity Scale (CGI-S) score from Baseline to Week 72

    Time frame: 72 weeks

  6. Secondary Efficacy End Point

    Change in knee extensor muscle strength as measured by handheld dynamometry (HHD)from Baseline to Week 72

    Time frame: 72 weeks

  7. Secondary Efficacy End Point 6

    -Change in hip flexor muscle strength as measured by HHD from Baseline to Week 72

    Time frame: 72 weeks

Other outcomes

  1. Safety End Point Adverse Event Reporting

    -Report the # of subjects with adverse events and incidence and severity of such adverse events (AEs)

    Time frame: 72weeks

07

Study locations

3 of 4 sites recruiting
  • Trial Not Offered in the U.S
    Needham, Massachusetts 02494, United States
    Terminated

    Not enrolling at this site.

  • Children's Hospital of Westmead
    Westmead, North South Wales, Australia
    Recruiting
  • Metabolics and Genetics in Canada (MAGIC)
    Calgary, Alberta, Canada
    Recruiting
  • Bristol Royal Hospital for Children Upper Maudlin Street Paul O'Gorman Building
    Bristol, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Apr 15, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Australia
Show site
  • Children's Hospital of Westmead · Westmead, Australia
Nov 9, 2026
Contact
Study contact changed: l•••@parexel.com→D•••@mightytx.com. See the current contact
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Metabolics and Genetics in Canada (MAGIC) · Calgary, CanadaContact c•••@magiccalgary.ca · •••3158→c•••@magiccalgary.ca · •••2509
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added — first site in Australia
    Show site
    • Children's Hospital of Westmead · Westmead, Australia
    Contact Study contact changed: l•••@parexel.com→D•••@mightytx.com. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Metabolics and Genetics in Canada (MAGIC) · Calgary, CanadaContact c•••@magiccalgary.ca · •••3158→c•••@magiccalgary.ca · •••2509
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07531251
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 2, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Rekha Sathyanarayana
Contact
rekha.sathyanarayana@stealthbt.com
617-762-2579
Dean Brostowin
Contact
Dean.Brostowin@mightytx.com
Rekha Sathyanarayana
study director · Stealth BioTherapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion